Ethyl 7-oxabicyclo[2.2.1]heptane-2-carboxylate | 91005-42-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧唑烯
• 英文名称: Ethyl 7-oxabicyclo[2.2.1]heptane-2-carboxylate
• CAS: 91005-42-4
• 化学式: C₉H₁₄O₃
• mdl: MFCD24393956
• 分子量: 170.21
• InChiKey: XXCACDZPLZGDIH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.888
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  7-氧杂二环[2.2.1]庚烷-3-羧酸 、 硫酸 、 羟基甲酸酯 、 乙醇 在 甲基叔丁基醚 、 水 、 Sodium sulfate-III 作用下， 反应 16.0h， 以yielding 34.03 g 7-oxa-bicyclo[2.2.1]heptane-2-carboxylic acid ethyl ester as a yellow oil的产率得到Ethyl 7-oxabicyclo[2.2.1]heptane-2-carboxylate
  参考文献：
  名称：

  PROCESS FOR THE MANUFACTURE OF 7-OXA-BICYCLO DERIVATIVES

  摘要：

  本发明涉及一种制备式I的7-氧代双环衍生物的方法。

  公开号：

  US20080154043A1

文献信息

• PYRAZOLE COMPOUND
  申请人：Sasaki Izumi

  公开号：US20130116296A1

  公开（公告）日：2013-05-09

  The present invention relates to a novel serotonin reuptake inhibitor which also exhibits 5-HT 2C antagonistic action (antidepressive and anxiolytic effects), in particular, 5-HT 2C inverse agonistic action comprising Compound (1): or a pharmaceutically acceptable salt thereof wherein R 1 , R 2 , R 3 and R 4 are independently hydrogen or C 1-6 alkyl etc.; R 5 is C 4-7 alkyl or —(CR 8 R 9 ) r -E; R 6 , R 7 , R 8 and R 9 are independently hydrogen, fluorine or C 1-6 alkyl; A is C 6-10 aryl or heteroaryl etc.; r is 1, 2, 3 or 4; E is C 3-8 cycloalkyl or C 6-10 aryl etc.; L is oxygen, sulfur or —NR 10 —; n is 1, 2 or 3; R 10 is hydrogen or C 1-6 alkyl etc.; and X is hydrogen or halogen etc.

  本发明涉及一种新型的血清素再摄取抑制剂，同时还表现出5-HT2C拮抗作用（抗抑郁和抗焦虑效果），特别是包括化合物（1）的5-HT2C逆作动作：或其药学上可接受的盐，其中R1、R2、R3和R4独立地为氢或C1-6烷基等；R5为C4-7烷基或—(CR8R9)r-E；R6、R7、R8和R9独立地为氢、氟或C1-6烷基；A为C6-10芳基或杂环芳基等；r为1、2、3或4；E为C3-8环烷基或C6-10芳基等；L为氧、硫或—NR10—；n为1、2或3；R10为氢或C1-6烷基等；X为氢或卤素等。
• [EN] BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS<br/>[FR] COMPOSÉS DE SULFONAMIDES BICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DU CANAL SODIQUE
  申请人：AMGEN INC

  公开号：WO2014201206A1

  公开（公告）日：2014-12-18

  The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.

  本发明提供了I式化合物及其药学上可接受的盐，它们是电压门控钠通道的抑制剂，特别是Nav1.7。这些化合物可用于治疗与钠通道活性有关的疾病，如疼痛障碍和瘙痒。还提供了含有本发明化合物的药物组合物。
• NOVEL SULFONIUM SALT, POLYMER, METHOD FOR PRODUCING THE POLYMER, RESIST COMPOSITION AND PATTERNING PROCESS
  申请人：OHASHI Masaki

  公开号：US20110189607A1

  公开（公告）日：2011-08-04

  There is disclosed a sulfonium salt represented by the following general formula (1). In the formula, X and Y each represents a group having a polymerizable functional group; Z represents a divalent hydrocarbon group having 1 to 33 carbon atoms optionally containing a hetero atom; R 1 represents a divalent hydrocarbon group having 1 to 36 carbon atoms optionally containing a hetero atom; and R 2 and R 3 each represents a monovalent hydrocarbon group having 1 to 30 carbon atoms optionally containing a hetero atom or R 2 and R 3 may be bonded with each other to form a ring together with a sulfur atom in the formula. There can be provided a sulfonium salt usable as a resist composition providing high resolution and excellent in LER in photolithography using a high energy beam such as an ArF excimer laser, an EUV light and an electron beam as a light source, a polymer obtained from the sulfonium salt, a resist composition containing the polymer and a patterning process using the resist composition.

  本发明公开了一种由下列通式（1）表示的烷基磺鎵盐。在该式中，X和Y分别表示具有可聚合官能团的基团；Z表示具有1至33个碳原子的双价碳氢基团，可选地含有一个杂原子；R1表示具有1至36个碳原子的双价碳氢基团，可选地含有一个杂原子；R2和R3分别表示具有1至30个碳原子的单价碳氢基团，可选地含有一个杂原子，或者R2和R3可以与该式中的硫原子一起形成环。可以提供一种可用作抗蚀剂组分的烷基磺鎵盐，该抗蚀剂组分在使用高能束如ArF准分子激光、EUV光和电子束作为光源的光刻工艺中，提供高分辨率和优异的LER，以及从该烷基磺鎵盐得到的聚合物、包含该聚合物的抗蚀剂组分和使用该抗蚀剂组分进行图案化处理的方法。
• BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS
  申请人：AMGEN INC.

  公开号：US20140371201A1

  公开（公告）日：2014-12-18

  The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.

  本发明提供了I式化合物及其药学上可接受的盐，该化合物是电压门控钠通道的抑制剂，尤其是Nav1.7。该化合物可用于治疗与钠通道活性相关的疾病，如疼痛障碍和瘙痒。还提供了含有本发明化合物的制药组合物。
• US5641784A
  申请人：——

  公开号：US5641784A

  公开（公告）日：1997-06-24